EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, THURSDAY, MARCH 31, 2022

Newswise MINNEAPOLIS A small, preliminary study of an investigational new drug being studied for mild cognitive impairment and mild dementia associated with Alzheimers disease suggests it is safe and may be associated with improvements in executive function, thinking and memory skills. The study is released today, March 31, 2022, and will be presented at the American Academy of Neurologys 74th Annual Meeting being held in person in Seattle, April 2 to 7, 2022 and virtually, April 24 to 26, 2022. The drug, called SAGE-718, is also in clinical trials for the treatment of cognitive impairment associated with Parkinsons disease and Huntingtons disease.

Cognitive impairment is often one of the earliest signs of Alzheimers disease, can be very difficult for patients and their families, and represents an area of great unmet medical need, said study author Aaron Koenig, MD, of Sage Therapeutics in Cambridge, Mass., the maker of the investigational drug. These results support further research with larger numbers of people to determine whether this therapy is safe and effective in treating cognitive impairment in Alzheimers disease and related disorders and in improving how well people can function independently in their everyday lives.

The study involved 26 people with an average age of 67. They had an average score of 20.7 points on a common cognitive test, indicating cognitive performance consistent with mild cognitive impairment or mild dementia. The participants took SAGE-718 daily for two weeks and were then followed for another two weeks. They completed tests of thinking and memory at the beginning of the study, at the end of treatment, and after one month. Both the participants and researchers knew that SAGE-718 was being administered.

The study was designed mainly to gather data on the drugs safety. There were no serious side effects of the drug. Five people had mild or moderate side effects believed to be related to the drug, such as headache or constipation.

After one month, the participants scores on the cognitive test had improved by an average of 2.3 points, to 22.8 points.

Koenig said some participants also had improvement in assessments of how well they were able to complete their daily activities, especially in complex activities such as using a computer, carrying out household chores, and managing their medications. This coincided with consistent improvement on multiple tests of executive functioning that were administered during the trial.

Koenig said, If replicated in future studies, such improvements suggest that this drug may eventually provide meaningful benefits to people in their everyday lives.

SAGE-718 is a type of drug called a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors.

The studys limitations include its small size and that participants and researchers knew that the drug was being administered, which could lead to bias.

The study was supported by Sage Therapeutics, Inc.

Learn more about brain health at BrainandLife.org, home of the American Academy of Neurologys free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

When posting to social media channels about this research, we encourage you to use the American Academy of Neurologys Annual Meeting hashtag #AANAM.

The American Academy of Neurology is the worlds largest association of neurologists and neuroscience professionals, with over 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, stroke, migraine, multiple sclerosis, concussion, Parkinsons disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

More here:
Preliminary Study: Drug May Be Safe in Those with Mild Cognitive Impairment, Mild Dementia - Newswise